Effect of induction therapy with bone mesenchymal stem cells on adenosine triphosphate levels in CD4+T cells determined by ImmuKnow assay in patients receiving renal transplantation
10.3969/j.issn.2095-4344.2014.37.012
- VernacularTitle:ImmuKnow法检测骨髓间充质干细胞诱导肾移植受者CD4+T细胞的三磷酸腺苷水平
- Author:
Shushang CHEN
;
Jinquan CAI
;
Chengyao WU
;
Zhen DENG
;
Lingfeng ZHU
;
Hao ZHOU
;
Qinghua WANG
;
Jianming TAN
- Publication Type:Journal Article
- Keywords:
bone marrow;
mesenchymal stem cells;
kidney transplantation;
adenosine triphosphate;
immunity
- From:
Chinese Journal of Tissue Engineering Research
2014;(37):5972-5976
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Bone mesenchymal stem cells have immunological regulation function both in vitro and in vivo, while the effect of bone marrow mesenchymal stem cells on CD4+T cellimmune function in patients receiving kidney transplantation remains unclear. OBJECTIVE:To explore the monitoring significance of CD4+T-cellimmune function by ImmuKnow assay and to determine the effect of induction therapy with bone marrow mesenchymal stem cells on cellimmune function in patients receiving kidney transplantation. METHODS:From January 2011 to June 2013, 24 patients receiving al ograft renal transplantation with autologous bone marrow mesenchymal stem cells were included and another 48 patients receiving al ograft renal transplantation and Simulect induction therapy with various matched preoperative characters served as controls. In both groups, adenosine triphosphate levels in CD4+T cells in the peripheral blood were determined by the ImmuKnow assay preoperatively and at 14, 30, 60, 90, 180 days postoperatively, as wel as during acute rejection and infection episodes. RESULTS AND CONCLUSION:During the 180 days postoperatively, fewer patients in the bone marrow mesenchymal stem cellgroup had acute rejection and injection than the Simulect group, but no significant differences were observed. Postoperative adenosine triphosphate levels in CD4+T cells were significantly lower than those determined preoperatively in both groups (P<0.05), while no significant differences were observed between the two groups. A total of 12 patients in the bone marrow mesenchymal stem cellgroup and 26 patients in the Simulect group had infection episodes, and the adenosine triphosphate levels in CD4+T cells during the infection episodes were lower than clinical stable patients in both groups (P<0.01). For patients receiving renal transplantation, induction therapy with bone marrow mesenchymal stem cells can effectively decrease the cellimmune function, which can be reflected by the adenosine triphosphate levels in CD4+T cells in the peripheral blood determined by the ImmuKnow assay.
